Talis Biomedical (NASDAQ:TLIS) Stock Price Down 1.7% – Should You Sell?

Talis Biomedical Co. (NASDAQ:TLIS) shares fell 1.7% on Tuesday . The company traded as low as $1.77 and last traded at $1.77. 139 shares changed hands during trading, a decline of 99% from the average session volume of 13,211 shares. The stock had previously closed at $1.80.

Talis Biomedical Stock Performance

The stock’s fifty day moving average is $1.77 and its two-hundred day moving average is $4.96. The firm has a market capitalization of $3.22 million, a price-to-earnings ratio of -0.06 and a beta of 1.58.

Institutional Investors Weigh In On Talis Biomedical

An institutional investor recently raised its position in Talis Biomedical stock. BML Capital Management LLC grew its stake in shares of Talis Biomedical Co. (NASDAQ:TLIS) by 481.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 248,702 shares of the company’s stock after acquiring an additional 205,959 shares during the period. Talis Biomedical comprises approximately 0.3% of BML Capital Management LLC’s holdings, making the stock its 24th biggest position. BML Capital Management LLC owned 13.66% of Talis Biomedical worth $460,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 43.77% of the stock is owned by institutional investors and hedge funds.

Talis Biomedical Company Profile

Talis Biomedical Corporation operates as a molecular diagnostic company, focusing on developing medical devices for infectious diseases and other conditions at the point of care in the United States. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Chicago, Illinois.